Iterum Therapeutics plc

NasdaqCM ITRM

Iterum Therapeutics plc Interest Coverage Ratio for the year ending December 31, 2023

Iterum Therapeutics plc Interest Coverage Ratio is NA for the year ending December 31, 2023. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Iterum Therapeutics plc Interest Coverage Ratio for the year ending December 31, 2022 was -17.69, a -15.17% change year over year.
Iterum Therapeutics plc Interest Coverage Ratio for the year ending December 31, 2021 was -15.36, a -541.27% change year over year.
Iterum Therapeutics plc Interest Coverage Ratio for the year ending December 31, 2020 was -2.40, a 97.97% change year over year.
Iterum Therapeutics plc Interest Coverage Ratio for the year ending December 31, 2019 was -118.26, a 33.85% change year over year.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

NasdaqCM: ITRM

Iterum Therapeutics plc

CEO	Mr. Corey N. Fishman
IPO Date	May 25, 2018
Location	Ireland
Headquarters	Fitzwilliam Court
Employees	14
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Clinical Trials Drugstores & Retail Pharmacies Personal Care Plastics Vaccines

Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key trends

Past 5 years